You are here

Novel Antivirals Based on 2-Deoxystreptamine

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 AI38732-01,
Agency Tracking Number: 29148
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Solicitation Year: N/A
Award Year: 1995
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
200 Boston Avenue, Suite 3000
Medford, MA 02155
United States
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Mark Wuonola
 () -
Business Contact
Phone: () -
Research Institution

We will develop a small molecule, orally active antiviral agents designed to halt replication of ththe level of transcription by inhibiting the Rev protein/RRE interaction. This protein/nucleic acidviral replication.(1-3) Zapp and coworkers demonstrated for the first time that a small molecule amineomycin B, could disrupt the Rev/RRE interaction.(4) The aminoglycoside antibiotics however possessbioavailability, and binding site selectivity profiles that require improvement.(5-9) In an effort twould like to step away from the aminoglycoside antibiotic skeleton and yet have our compounds retaithe parent molecule. We will use as our central building block 2-deoxystreptamine, the same aminocycvirtually all of the naturally occurring aminoglycoside antibiotics. Derivatization of 2-deoxystreptcarbohydrate moieties, whose functional groups are in accord with our proprietary structure activityafford neomycin B mimics that display the desired inhibitory properties while having improved therapDetermination of compound efficacy is performed in house using cell-based and multiple in vitro assa

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government